Amarillo Biosciences Announces Phase II Study Of Orally Administered Interferon Alpha In The Treatment Of Oral Warts In HIV-Positive Patients

AMARILLO, TX -- (MARKET WIRE) -- December 11, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that four clinical sites are ready to enroll patients in a Phase 2 study to test low-dose interferon alpha lozenges administered orally to human immunodeficiency virus (HIV)-positive subjects with oral warts. Viral lesions of the mouth in patients infected with HIV are common and may be indicative of disease progression. One of the causes of oral lesions is a group of DNA viruses, human papilloma viruses, which induce hyperplastic lesions in the oral soft tissue such as papillomas, warts, condylomata and focal epithelial hyperplasia.